Rev Esp Quimioter 2022;35(Suppl.3):74-79
Current management of CMV infection in cancer patients (solid tumors). Epidemiology and therapeutic strategies
VÍCTOR GARCÍA-BUSTOS, MIGUEL SALAVERT, ROSA BLANES, DAFNE CABAÑERO, MARINO BLANES
Published: 24 October 2022
Little evidence is available regarding the incidence of CMV disease in patients with solid cancers. Latest data show that approximately 50 % of these patients with CMV PCR positivity developed clinically relevant CMV-viremia, and would require specific therapy. In the clinical arena, CMV reactivation is an important differential diagnosis in the infectological work up of these patients, but guidelines of management on this subject are not yet available. CMV reactivation should be considered during differential diagnosis for patients with a severe decline in lymphocyte counts when receiving chemoradiotherapy or immunochemotherapy with lymphocyte-depleting or blocking agents. Monitoring of CMV reactivation followed by the implementation of preemptive strategies or the establishment of early antiviral treatment improves the prognosis and reduces the morbidity and mortality of these patients.
Rev Esp Quimioter 2022; 35(Suppl.3):74-79 [Full-text PDF]